{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:51Z","timestamp":1791300531921,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.autrev.2014.01.053","type":"journal-article","created":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T06:02:03Z","timestamp":1390629723000},"page":"685-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":284,"title":["14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends"],"prefix":"10.1016","volume":"13","author":[{"given":"Doruk","family":"Erkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassyanne L.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Danowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Ortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.01.053_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the preliminary classification criteria for antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2001.03178.x","article-title":"Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant","volume":"115","author":"Tripodi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0030","unstructured":"Lixiana\u00ae (Edoxaban) 15mg and 30mg tablets: first marketing approval by the Ministry of Health, Labor and Welfare, Japan 04\/22\/2011."},{"key":"10.1016\/j.autrev.2014.01.053_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0720","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix)","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0045","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0050","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin for the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0725","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jth.12038","volume":"11","author":"Ageno","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12052","article-title":"Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from British Committee for Standards in Haematology","volume":"159","author":"Baglin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH10-08-0511","article-title":"Rivaroxaban and false positive lupus anticoagulant testing","volume":"105","author":"Merriman","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0075","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","article-title":"Detection of lupus anticoagulants in the presence of rivaroxaban using Taipan snake venom time","volume":"9","author":"van Os","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.21718","article-title":"Laboratory monitoring of new anticoagulants","volume":"85","author":"Castellone","year":"2010","journal-title":"Am J Haematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory assessments of new anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0090","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban \u2014 an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0730","article-title":"Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","author":"Martinuzzo","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2014.01.053_bb0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"2 Suppl.","key":"10.1016\/j.autrev.2014.01.053_bb0110","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2014.01.053_bb0115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0120","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/j.1538-7836.2006.01961.x","article-title":"Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia","volume":"4","author":"Holtan","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jvs.2008.02.052","article-title":"Superficial femoral artery thrombosis as a cause for distal embolism in primary antiphospholipid syndrome","volume":"48","author":"Lauvao","year":"2008","journal-title":"J Vasc Surg"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.053_bb0130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0135","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2008.02973.x","article-title":"Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal","volume":"6","author":"Elalamy","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0140","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0145","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1538-7836.2008.02972.x","article-title":"Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal","volume":"6","author":"Warkentin","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0150","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0155","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1160\/TH10-05-0284","article-title":"Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke","volume":"104","author":"Salem","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0160","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2014.01.053_bb0165","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.01.053_bb0170","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"issue":"576","key":"10.1016\/j.autrev.2014.01.053_bb0735","first-page":"e7","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0180","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2014.01.053_bb0185","first-page":"174","article-title":"Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty","volume":"144","author":"Johnson","year":"1979","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.autrev.2014.01.053_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0195","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.1780301219","article-title":"Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? [letter]","volume":"30","author":"Wallace","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2014.01.053_bb0210","first-page":"S297","article-title":"Arterial thrombotic events (TE) in SLE: the Baltimore Lupus Cohort study [abstract]","volume":"37","author":"Petri","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0220","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203306069972","article-title":"Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus","volume":"15","author":"de Leeuw","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0225","first-page":"622","article-title":"Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus","volume":"32","author":"Mok","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0235","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/kei014","article-title":"Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events","volume":"44","author":"Ho","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.01.053_bb0240","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.21224","article-title":"Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups","volume":"52","author":"Mok","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0740","series-title":"APLA-LACA","article-title":"Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, but only in antiphospholipid positive patients","author":"Petri","year":"2013"},{"key":"10.1016\/j.autrev.2014.01.053_bb0250","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.01.053_bb0255","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Anti-thrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2014.01.053_bb0745","first-page":"279","article-title":"The effects of hydroxychloroquine on antiphospholipid antibodies in SLE Patients [abstract]","volume":"60","author":"Broder","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0270","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/ard.2004.031856","article-title":"Real world experience with antiphospholipid antibody tests: how stable are results over time?","volume":"64","author":"Erkan","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0750","series-title":"ACR","article-title":"Effect of hydroxychloroquine (HCQ) on the annexin A5 resistance assay (AnxA5-RA) in antiphospholipid antibody (aPL)-positive patients: preliminary results of an ongoing prospective study","author":"Levine","year":"2012"},{"key":"10.1016\/j.autrev.2014.01.053_bb0280","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/ard.2006.067835","article-title":"Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus","volume":"66","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0285","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archdermatol.2011.2558","article-title":"Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study","volume":"148","author":"Franc\u00e8s","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0290","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2014.01.053_bb0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/kel402","article-title":"Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases","volume":"46","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.01.053_bb0300","first-page":"139","article-title":"Immunomodulatory effects of HMG-CoA reductase inhibitors","volume":"51","author":"Danesh","year":"2003","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.autrev.2014.01.053_bb0305","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"2","author":"Ferrara","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0310","first-page":"18","article-title":"Effect of rosuvastatin on VCAM-1 expression by HIVEC exposed to APS serum in an in vitro model","volume":"25","author":"Martinez-Martinez","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0315","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0320","first-page":"3453","article-title":"Neutrophil activation by the tissue factor\/Factor VIIa\/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2014.01.053_bb0325","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0330","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/humrep\/des288","article-title":"Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function","volume":"27","author":"Odiari","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.autrev.2014.01.053_bb0335","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00011-013-0652-x","article-title":"Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort","volume":"62","author":"Majka","year":"2013","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2014.01.053_bb0340","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/acr.20122","article-title":"Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus","volume":"62","author":"Urowitz","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2014.01.053_bb0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2010.10.004","article-title":"Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients","volume":"10","author":"Medina","year":"2011","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.autrev.2014.01.053_bb0350","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0961203309357765","article-title":"High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome","volume":"19","author":"Ames","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0355","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0360","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/art.1780400509","article-title":"Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression","volume":"40","author":"Cuadrado","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0365","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1191\/0961203303lu448rr","article-title":"The molecular basis of antiphospholipid syndrome","volume":"12","author":"Gharavi","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0755","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","author":"Erkan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0760","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jri.2009.11.007","article-title":"Statins for the treatment of obstetric complications in antiphospholipid syndrome?","volume":"84","author":"Lockshin","year":"2010","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0380","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"350","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0385","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.053_bb0390","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/00000542-200612000-00027","article-title":"Improved postoperative outcomes associated with preoperative statin therapy","volume":"105","author":"Hindler","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.autrev.2014.01.053_bb0395","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1213\/01\/ane.0000309024.28586.70","volume":"106","author":"Fleisher","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1016\/j.autrev.2014.01.053_bb0400","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.thromres.2004.06.019","article-title":"The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases","volume":"114","author":"Youinou","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2014.01.053_bb0405","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome\u2014new directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.053_bb0410","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0415","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/08916930400008524","article-title":"CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW\/BXSB mice","volume":"37","author":"Akkerman","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2014.01.053_bb0420","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.053_bb0765","series-title":"APLA-LACA","article-title":"The effect of rituximab on the antiphospholipid antibody profile","author":"Aguiar","year":"2013"},{"key":"10.1016\/j.autrev.2014.01.053_bb0770","first-page":"ECR34","article-title":"Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome","volume":"89","author":"Erdozain","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.01.053_bb0435","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0961203307085251","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11926-009-0074-5","article-title":"Use of rituximab in the antiphospholipid syndrome","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2014.01.053_bb0445","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0450","first-page":"4078","article-title":"Rituximab in the Primary Antiphospholipid Syndrome (PAPS)","volume":"52","author":"Tenedios","year":"2005","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2014.01.053_bb0455","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00277-006-0226-x","article-title":"Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome","volume":"86","author":"Ames","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0460","first-page":"652","article-title":"Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome [abstract]","volume":"114","author":"Tommasino","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2014.01.053_bb0465","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203311400115","article-title":"Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome","volume":"20","author":"Sciascia","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0470","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00277-005-0028-6","article-title":"Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab\u2014monitoring of antiphospholipid and anti-GP antibodies: a case report","volume":"85","author":"Trappe","year":"2006","journal-title":"Ann Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.01.053_bb0475","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s10067-010-1506-3","article-title":"Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis","volume":"32","author":"Costa","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0480","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1525-1594.2010.01068.x","article-title":"Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation","volume":"35","author":"Tsagalis","year":"2011","journal-title":"Artif Organs"},{"key":"10.1016\/j.autrev.2014.01.053_bb0775","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.053_bb0490","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"Rituximab in antiphospholipid syndrome (RITAPS) \u2014 a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0505","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0510","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2014.01.053_bb0515","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/01.CIR.99.15.1997","article-title":"Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo","volume":"99","author":"Pierangeli","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2014.01.053_bb0520","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1172\/JCI118276","article-title":"Activation of cultured vascular endothelial cells by antiphospholipid antibodies","volume":"96","author":"Simantov","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2014.01.053_bb0785","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000087963","article-title":"The complement system at the fetomaternal interface","volume":"89","author":"Bulla","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.autrev.2014.01.053_bb0530","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2006-04-001206","article-title":"Current concepts on the pathogenesis of the antiphospholipid syndrome","volume":"109","author":"Giannakopoulos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.01.053_bb0535","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.molimm.2010.05.009","article-title":"Complement activation on platelets: implications for vascular inflammation and thrombosis","volume":"47","author":"Peerschke","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0540","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor crosstalk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0545","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.01.053_bb0550","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement surface recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0790","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0560","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.287.5452.498","article-title":"A critical role for murine complement regulator crry in fetomaternal tolerance","volume":"287","author":"Xu","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.autrev.2014.01.053_bb0565","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0570","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0575","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0795","series-title":"APLA-LACA","article-title":"Discordant aPTT and anti-FXa values in a catastrophic antiphospholipid syndrome patient receiving intravenous unfractionated heparin","author":"Khianey","year":"2013"},{"key":"10.1016\/j.autrev.2014.01.053_bb0585","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0590","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0595","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0600","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic\u2013uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.053_bb0800","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/petr.12151","article-title":"Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation","volume":"17","author":"Sinibaldi","year":"2013","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.autrev.2014.01.053_bb0610","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1093\/emboj\/18.19.5166","article-title":"Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure","volume":"18","author":"Bouma","year":"1999","journal-title":"Embo J"},{"key":"10.1016\/j.autrev.2014.01.053_bb0615","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4049\/jimmunol.152.2.653","article-title":"The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281\u2013Cys288) and a region recognized by anticardiolipin antibodies","volume":"152","author":"Hunt","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0620","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI","volume":"95","author":"Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.053_bb0625","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies","volume":"169","author":"Iverson","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0630","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/art.22306","article-title":"Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43","volume":"56","author":"Ioannou","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0635","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2014.01.053_bb0640","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2011.07.024","article-title":"Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies","volume":"49","author":"Pericleous","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0645","first-page":"S563","article-title":"Peptide and NMR spectroscopy studies of recombinant domain I confirm conformationally correct domain I and non-linear epitope binding to anti-domain I antiphospholipid antibodies","volume":"62","author":"Pericleous","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0650","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.10130","article-title":"Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo","volume":"46","author":"Gharavi","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.053_bb0655","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1191\/0961203306lu2315oa","article-title":"A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice","volume":"15","author":"Ostertag","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0660","doi-asserted-by":"crossref","first-page":"J209","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.053_bb0665","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1073\/pnas.96.9.5164","article-title":"Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides","volume":"96","author":"Blank","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.053_bb0670","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaut.2004.01.002","article-title":"A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo","volume":"22","author":"Pierangeli","year":"2004","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.053_bb0675","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12016-012-8342-y","article-title":"Vitamin D in systemic and organ-specific autoimmune diseases","volume":"45","author":"Agmon-Levin","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2014.01.053_bb0680","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.053_bb0685","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"Andreoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0690","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jbspin.2010.02.043","article-title":"High frequency of vitamin D insufficiency in primary antiphospholipid syndrome","volume":"77","author":"Klack","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2014.01.053_bb0805","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0961203310372938","article-title":"Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass","volume":"19","author":"Paupitz","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.053_bb0700","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4081\/reumatismo.2012.307","article-title":"Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease","volume":"64","author":"Piantoni","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2014.01.053_bb0810","article-title":"Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity","author":"Ota","year":"2013","journal-title":"Hum Reprod"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T16:42:52Z","timestamp":1716482572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1568997214000652"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.053","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}